Table 2.
Treatment characteristics prior to the start of chemotherapy
| Characteristic (median, range) | Cinvanti (n = 101) | Emend IV (n = 101) | Generic alternatives (n = 92) |
|---|---|---|---|
| MEC/HEC agent | |||
| Carboplatin | 40.6% | 34.6% | 20.6% |
| Cisplatin | 4.0% | 6.9% | 10.9% |
| Oxaliplatin | 12.9% | 7.9% | 19.6% |
| Doxorubicin | 36.6% | 43.6% | 41.3% |
| Number of cycles (median) | 3 (1 to ≥ 8) | 3 (1 to ≥ 8) | 3 (1 to ≥ 8) |
| Total number of cycles given | 495 | 458 | 479 |
| Vesicant part of treatment | 55.4% | 57.4% | 47.8% |
| Number of vesicants (median) | 1 (0 to 2) | 1 (0 to 2) | 0 (0 to 2) |
| NK1 dose | 130 mg | 150 mg | 150 mg |
| CVA for NK1 infusion | 97.0% | 86.1% | 94.6% |
| NK1 infusion duration | |||
| 20 min | 5.9% | 11.9% | 40.2% |
| 30 min | 42.6% | 56.4% | 14.1% |
| 40 min | 3.0% | 4.0% | 1.1% |
| Other | 48.5% | 27.7% | 44.6% |
| IV fluid rate | |||
| < 100 mL/h | 33.7% | 14.8% | 6.5% |
| ≥ 100 mL/h | 40.6% | 65.4% | 58.7% |
| Not documented | 25.7% | 19.8% | 34.8% |
| Dexamethasone given | 97.0% | 100% | 100% |
| Dexamethasone given IV | 97.0% | 99.0% | 99.0% |
| Dexamethasone dose (median) | 10 mg (1 to 20) | 12 (4 to 40) | 12 (10 to 12) |
| Dexamethasone added to IV bag | 16.8% | 11.9% | 52.2% |
| Palonosetron used | 90.1% | 91.0% | 95.6% |
Abbreviations: 5HT3 serotonin 5-HT3 receptor antagonist, NK1 neurokinin 1 receptor antagonist, CVA central venous access, IV intravenous, MEC moderately emetogenic chemotherapy, HEC highly emetogenic chemotherapy